Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
7.13
-0.10 (-1.38%)
At close: Aug 15, 2025, 4:00 PM
7.22
+0.09 (1.26%)
After-hours: Aug 15, 2025, 5:54 PM EDT
Abeona Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 163.54 | 23.36 | 14.47 | 14.22 | 32.94 | 12.6 | Upgrade
|
Short-Term Investments | 61.98 | 74.36 | 37.75 | 37.93 | 12.09 | 82.44 | Upgrade
|
Cash & Short-Term Investments | 225.52 | 97.72 | 52.23 | 52.15 | 45.02 | 95.03 | Upgrade
|
Cash Growth | 83.78% | 87.11% | 0.15% | 15.82% | -52.62% | -26.48% | Upgrade
|
Accounts Receivable | - | - | - | - | 3 | - | Upgrade
|
Other Receivables | 1.63 | 1.65 | 2.44 | 0.19 | - | - | Upgrade
|
Receivables | 1.63 | 1.65 | 2.44 | 0.19 | 3 | - | Upgrade
|
Prepaid Expenses | 2.09 | 1.14 | 0.73 | 0.42 | 2.38 | 2.71 | Upgrade
|
Restricted Cash | 0.34 | 0.34 | 0.34 | 0.34 | 5.89 | - | Upgrade
|
Total Current Assets | 232.26 | 100.85 | 55.74 | 53.1 | 56.29 | 97.74 | Upgrade
|
Property, Plant & Equipment | 13.63 | 7.98 | 7.99 | 11.07 | 21.74 | 18.35 | Upgrade
|
Goodwill | - | - | - | - | - | 32.47 | Upgrade
|
Other Intangible Assets | - | - | - | - | 1.38 | 1.5 | Upgrade
|
Other Long-Term Assets | 0.34 | 0.1 | 0.28 | 0.04 | 0.17 | 1.14 | Upgrade
|
Total Assets | 246.23 | 108.93 | 64 | 64.21 | 79.59 | 151.2 | Upgrade
|
Accounts Payable | 7.34 | 3.44 | 1.86 | 1.81 | 4.33 | 4.7 | Upgrade
|
Accrued Expenses | 21.01 | 6.33 | 5.99 | 3.99 | 5.59 | 3.41 | Upgrade
|
Current Portion of Long-Term Debt | 5.56 | 5.93 | - | - | - | 0.33 | Upgrade
|
Current Portion of Leases | 0.54 | 0.82 | 1 | 1.77 | 1.82 | 1.71 | Upgrade
|
Current Unearned Revenue | - | - | - | - | - | 0.3 | Upgrade
|
Other Current Liabilities | 0.08 | 0.06 | 4.58 | 0.2 | 4.9 | 31.52 | Upgrade
|
Total Current Liabilities | 34.52 | 16.59 | 13.42 | 7.78 | 16.62 | 41.96 | Upgrade
|
Long-Term Debt | 14.01 | 13.04 | - | - | - | 1.43 | Upgrade
|
Long-Term Leases | 3.98 | 3.26 | 4.4 | 5.85 | 7.56 | 5.26 | Upgrade
|
Other Long-Term Liabilities | 30.16 | 32.01 | 31.35 | 23.82 | 13.04 | - | Upgrade
|
Total Liabilities | 82.66 | 64.9 | 49.18 | 37.45 | 37.22 | 48.65 | Upgrade
|
Common Stock | 0.51 | 0.46 | 0.27 | 0.18 | 1.47 | 0.96 | Upgrade
|
Additional Paid-In Capital | 879.56 | 856.82 | 764.15 | 722.05 | 696.56 | 672.3 | Upgrade
|
Retained Earnings | -716.45 | -813.26 | -749.52 | -695.34 | -655.64 | -570.7 | Upgrade
|
Comprehensive Income & Other | -0.05 | 0.01 | -0.07 | -0.13 | -0.03 | -0.01 | Upgrade
|
Shareholders' Equity | 163.58 | 44.03 | 14.83 | 26.76 | 42.37 | 102.55 | Upgrade
|
Total Liabilities & Equity | 246.23 | 108.93 | 64 | 64.21 | 79.59 | 151.2 | Upgrade
|
Total Debt | 24.08 | 23.05 | 5.4 | 7.63 | 9.38 | 8.73 | Upgrade
|
Net Cash (Debt) | 201.44 | 74.67 | 46.83 | 44.52 | 35.65 | 86.3 | Upgrade
|
Net Cash Growth | 102.37% | 59.47% | 5.17% | 24.90% | -58.70% | -28.86% | Upgrade
|
Net Cash Per Share | 3.55 | 1.82 | 2.19 | 5.66 | 9.05 | 23.28 | Upgrade
|
Filing Date Shares Outstanding | 51.28 | 48.53 | 27.36 | 17.71 | 5.9 | 3.95 | Upgrade
|
Total Common Shares Outstanding | 51.25 | 45.64 | 26.52 | 17.72 | 5.89 | 3.85 | Upgrade
|
Working Capital | 197.75 | 84.27 | 42.32 | 45.32 | 39.67 | 55.78 | Upgrade
|
Book Value Per Share | 3.19 | 0.96 | 0.56 | 1.51 | 7.20 | 26.67 | Upgrade
|
Tangible Book Value | 163.58 | 44.03 | 14.83 | 26.76 | 40.98 | 68.59 | Upgrade
|
Tangible Book Value Per Share | 3.19 | 0.96 | 0.56 | 1.51 | 6.96 | 17.84 | Upgrade
|
Machinery | - | 9.98 | 7.92 | 9.02 | 10.98 | 9.98 | Upgrade
|
Construction In Progress | - | 0.62 | - | - | 3.22 | 0.07 | Upgrade
|
Leasehold Improvements | - | 8.81 | 8.6 | 8.61 | 8.6 | 8.6 | Upgrade
|
Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.